Drug Profile
Research programme: HIV replication inhibitors - Pfizer
Alternative Names: PF 821386; PF-821385; UK-201844Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Pfizer
- Class Piperazines; Pyridines; Small molecules
- Mechanism of Action HIV replication inhibitors; Viral envelope protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported HIV infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in HIV-infections in USA
- 17 Apr 2008 Antimicrobial and pharmacokinetics data from a preclinical trial in HIV infections presented at the 21st International Conference on Antiviral Research (ICAR-2008)
- 23 Feb 2006 Preclinical trials in HIV infections in USA (unspecified route)